New Delhi, K.Lyngkot 27: Ka National Regulator, Drugs Controller General of India (DCGI), ka la ai jingbit ia ka market authorisation jong artylli ki dawai tika COVID 19, Covaxin bad Covishield mynta ka sngi bad kane ka jingai jingbit ka shong ha ka jinglah ban pyndep ia katto katne ki kam.
Ka Subject Expert Committee (SEC) jong ka Central Drugs Standard Control Organization (CDSCO) ka la ai jingmut ban kyntiew ia ka jingithuh ia ki dawai tika na ka ‘jingpyndonkamkyrkieh’ ha ki kam ba donkam sha ka jingai ia ka jingbit ban pyndonkam ia kine ki dawai tika ha ka 19 tarik u Kyllalyngkot, 2022 na ka bynta ki Rangbah haba lah ban pyndep ia katto katne ki kamram.
Ka kynhun ai jingbit kaba la iathuh da ka sorkar pdeng na ka bynta kine ar tylli ki dawai tika COVID19, Covaxin bad Covishield ha ka ri da ka DCGI ka shong ha kine harum, Ka kynhun kan pynpoi ia ki jingshem jong ki jingwad bniah shaphang kine ki dawai tika ba long shabar ri man ka 6 bnai lane ha ka por ba ioh ia kine ki jingshem, katba kloi.
Yn pynbiang ia ki dawai tika na ka bynta kane ka samoi jong ka prokram bad ia baroh ki jingai dawai tika ha ka ri yn kyntiew ha ka rynsan CoWINbad yn dang bteng ban peit bniah ia ka Adverse Event Following Immunization [AEFI] bad ka Adverse Event of Special Interest [AESI].
Ka kynhun kan ai ia ki jingshem jong ka jingwad bniah shaphang ka jingshngain jong kine ki dawai tika man ka 6 bnai lane ha ka por ba ka ioh ia kine ki jingshem, katba kloi katkum ki kyndon NDCT Rules, 2019.
Ka rukom treikam jong ka Sorkar India ka la paw shai ha ka rukom ialeh pyrshah ia ka khlam COVID 19. Kane ka jingai jingbit da ka DCGI na ka bynta ka market authorization jong kine ar tylli ki dawai tika ha ka ri ka pyni ia ka jingstet jong ki kam ban ai jingiada ia ki briew jong ka ri bad ka jingstet ban shim ia ki rai kiba donkam kiba la ai jingiarap bha ia ki briew ha ka por jong kane ka khlam.
Lah ban shu kdew hangne ba napdeng ki kynhun ai jingbit kiba khlain ha kylleng ka pyrthei, ka dei tang ka United States Food and Drug Administration (USFDA) bad ka Medicines and Healthcare products Regulatory Agency (MHRA) jong ka UK kiba la ai ia kum kane ka jingbit “conditional market authorization” na ka bynta ki dawai tika Pfizer bad AstraZeneca.
Ka “Conditional Market Authorization” ka dei ka thup thymmai jong ka market authorization kaba la mih ha kane ka por jong ka khlam COVID19. Ka rukom ai jingbit ha kane ka rukom ka long kaba la pynstet khnang ban lah ban ioh ia katto katne ki mar khnang ban pyndap ia ka jingdonkam ia ki dawai ne ki dawai tika.
La sdang ia ka jingai dawai tika COVID 19 ha kylleng ka ri India ha ka 16 tarik u Kyllalyngkot, 2021. Haduh mynta, la dep ai palat 160 klur ki dose dawai tika. Ka Sorkar Pdeng ka kut jingmut ban pynstet bad pyniar ia ka kam ai dawai tika COVID 19 ha kylleng ka ri. La pdiang shuh shuhia ki thup bapher bapher ha ka kam ai dawai tika COVID bad ia kane la sdang naduh ka 3 tarik u Kyllalyngkot 2022.
